Palatin Technologies: Funding, Investors & Team (Sep 2026)
Palatin Technologies is a company that specializes in the development of specific peptide therapeutics to address medical conditions in need of treatment options, while also holding commercial potential. The company's research focuses on manipulating the activity of melanocortin and natriuretic peptide receptor systems. Their main clinical product, bremelanotide, is aimed at providing a solution for female sexual dysfunction (FSD). Additionally, Palatin Technologies has various drug candidates and development programs targeting obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. The company is currently directing their efforts towards designing and developing receptor-specific melanocortin agonists primarily for inflammation and autoimmune conditions, especially in ocular diseases. By utilizing endogenous melanocortin pathways, their therapeutics aim to alleviate damaging inflammation and facilitate the healing process. Notably, studies have indicated that melanocortin agonists have the potential to prevent and reverse inflammation in disease models, particularly in the eyes and intestine, which are among Palatin Technologies' areas of focus.
Palatin Technologies has raised $29.0M across 4 funding rounds on record, the most recent an undisclosed round of $18.2M announced in Nov 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Palatin Technologies Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Palatin Technologies Funding Rounds
Palatin Technologies raised $5.0M in an undisclosed round announced in Oct 2023.
1.3 years later, an undisclosed round of $4.7M was announced in Feb 2025.
3 months later, an undisclosed round of $1.1M was announced in May 2025.
6 months later, an undisclosed round of $18.2M was announced in Nov 2025.
Palatin Technologies Founders and Leadership Team
Contact details for the Palatin Technologies team: 1 of 2 have an email address on file.
Start 14-day free trial →Palatin Technologies Funding Compared to Other Biotechnology Startups
Palatin Technologies' latest round of $18.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Palatin Technologies in Biotechnology and Cranbury
Companies Similar to Palatin Technologies
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Palatin Technologies Funding FAQs
What does Palatin Technologies do?
Palatin Technologies is a company that specializes in the development of specific peptide therapeutics to address medical conditions in need of treatment options, while also holding commercial potential. The company's research focuses on manipulating the activity of melanocortin and natriuretic peptide receptor systems. Their main clinical product, bremelanotide, is aimed at providing a solution for female sexual dysfunction (FSD). Additionally, Palatin Technologies has various drug candidates and development programs targeting obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases. The company is currently directing their efforts towards designing and developing receptor-specific melanocortin agonists primarily for inflammation and autoimmune conditions, especially in ocular diseases. By utilizing endogenous melanocortin pathways, their therapeutics aim to alleviate damaging inflammation and facilitate the healing process. Notably, studies have indicated that melanocortin agonists have the potential to prevent and reverse inflammation in disease models, particularly in the eyes and intestine, which are among Palatin Technologies' areas of focus.
How much funding has Palatin Technologies raised?
Palatin Technologies has raised $29.0M across 4 rounds on record. The most recent is an undisclosed round of $18.2M announced in Nov 2025.
When did Palatin Technologies last raise funding?
Palatin Technologies' most recent funding round on record is an undisclosed round of $18.2M, announced in Nov 2025.
Who founded Palatin Technologies?
FundedIQ lists Carl Spana (Founder), John Prendergast (Founder) at Palatin Technologies.
Where is Palatin Technologies headquartered?
Palatin Technologies is based in Cranbury, New Jersey, United States.
How many employees does Palatin Technologies have?
Palatin Technologies is in the 51-100 employee band.
How does Palatin Technologies' funding compare to other Biotechnology startups?
Palatin Technologies' latest round of $18.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Palatin Technologies Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Palatin Technologies is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.